681 related articles for article (PubMed ID: 23074134)
1. Evaluation of clinical and safety outcomes associated with conversion from brand-name to generic tacrolimus in transplant recipients enrolled in an integrated health care system.
Spence MM; Nguyen LM; Hui RL; Chan J
Pharmacotherapy; 2012 Nov; 32(11):981-7. PubMed ID: 23074134
[TBL] [Abstract][Full Text] [Related]
2. A multicenter experience with generic tacrolimus conversion.
McDevitt-Potter LM; Sadaka B; Tichy EM; Rogers CC; Gabardi S
Transplantation; 2011 Sep; 92(6):653-7. PubMed ID: 21788920
[TBL] [Abstract][Full Text] [Related]
3. Clinical outcomes associated with conversion from brand-name to generic tacrolimus in hospitalized kidney transplant recipients.
Heavner MS; Tichy EM; Yazdi M; Formica RN; Kulkarni S; Emre S
Am J Health Syst Pharm; 2013 Sep; 70(17):1507-12. PubMed ID: 23943182
[TBL] [Abstract][Full Text] [Related]
4. Transition from brand to generic tacrolimus is associated with a decrease in trough blood concentration in pediatric heart transplant recipients.
Duong SQ; Lal AK; Joshi R; Feingold B; Venkataramanan R
Pediatr Transplant; 2015 Dec; 19(8):911-7. PubMed ID: 26497983
[TBL] [Abstract][Full Text] [Related]
5. Generics: are all immunosuppression agents created equally?
Hauch A; John M; Smith A; Dortonne I; Patel U; Kandil E; Killackey M; Paramesh A; Lee B; Zhang R; Buell JF
Surgery; 2015 Oct; 158(4):1049-54; discussion 1054-5. PubMed ID: 26206317
[TBL] [Abstract][Full Text] [Related]
6. Generic immunosuppression in solid organ transplantation: a Canadian perspective.
Harrison JJ; Schiff JR; Coursol CJ; Daley CJ; Dipchand AI; Heywood NM; Keough-Ryan TM; Keown PA; Levy GA; Lien DC; Wichart JR; Cantarovich M
Transplantation; 2012 Apr; 93(7):657-65. PubMed ID: 22267158
[TBL] [Abstract][Full Text] [Related]
7. Case report: Inability to achieve a therapeutic dose of tacrolimus in a pediatric allogeneic stem cell transplant patient after generic substitution.
Madian AG; Panigrahi A; Perera MA; Pinto N
BMC Pharmacol Toxicol; 2014 Dec; 15():69. PubMed ID: 25472557
[TBL] [Abstract][Full Text] [Related]
8. The clinical impact of 1:1 conversion from Neoral to a generic cyclosporine (Gengraf) in renal transplant recipients with stable graft function.
Qazi YA; Forrest A; Tornatore K; Venuto RC
Clin Transplant; 2006; 20(3):313-7. PubMed ID: 16824147
[TBL] [Abstract][Full Text] [Related]
9. Conversion to tacrolimus extended-release formulation: short-term clinical results.
Gallego-Valcarce E; Ortega-Cerrato A; Llamas-Fuentes F; Martinez-Fernandez G; Perez-Martinez J; Gomez-Roldan C
Transplant Proc; 2009; 41(6):2326-7. PubMed ID: 19715909
[TBL] [Abstract][Full Text] [Related]
10. A randomized, prospective, pharmacoeconomic trial of neoral 2-hour postdose concentration monitoring versus tacrolimus trough concentration monitoring in de novo liver transplant recipients.
Shenoy S; Hardinger KL; Crippin J; Korenblat K; Lisker-Melman M; Lowell JA; Chapman W
Liver Transpl; 2008 Feb; 14(2):173-80. PubMed ID: 18236391
[TBL] [Abstract][Full Text] [Related]
11. Once-daily tacrolimus extended release formulation: experience at 2 years postconversion from a Prograf-based regimen in stable liver transplant recipients.
Florman S; Alloway R; Kalayoglu M; Punch J; Bak T; Melancon J; Klintmalm G; Busque S; Charlton M; Lake J; Dhadda S; Wisemandle K; Wirth M; Fitzsimmons W; Holman J; First MR
Transplantation; 2007 Jun; 83(12):1639-42. PubMed ID: 17589349
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics and Clinical Outcomes of Generic Tacrolimus (Hexal) Versus Branded Tacrolimus in De Novo Kidney Transplant Patients: A Multicenter, Randomized Trial.
Arns W; Huppertz A; Rath T; Ziefle S; Rump LC; Hansen A; Budde K; Lehner LJ; Shipkova M; Baeumer D; Kroeger I; Sieder C; Klein T; Schenker P
Transplantation; 2017 Nov; 101(11):2780-2788. PubMed ID: 28658202
[TBL] [Abstract][Full Text] [Related]
13. Bioequivalence between innovator and generic tacrolimus in liver and kidney transplant recipients: A randomized, crossover clinical trial.
Alloway RR; Vinks AA; Fukuda T; Mizuno T; King EC; Zou Y; Jiang W; Woodle ES; Tremblay S; Klawitter J; Klawitter J; Christians U
PLoS Med; 2017 Nov; 14(11):e1002428. PubMed ID: 29135993
[TBL] [Abstract][Full Text] [Related]
14. Clinical pharmacokinetics of tacrolimus in rescue therapy after renal transplantation.
Budde K; Fritsche L; Mai I; Bauer S; Smettan S; Waiser J; Hofmann T; Hauser I; Reinke P; Neumayer HH
Int J Clin Pharmacol Ther; 1996 Nov; 34(11):493-7. PubMed ID: 8937932
[TBL] [Abstract][Full Text] [Related]
15. Nationwide conversion to generic tacrolimus in pediatric kidney transplant recipients.
Naicker D; Reed PW; Ronaldson J; Kara T; Wong W; Prestidge C
Pediatr Nephrol; 2017 Nov; 32(11):2125-2131. PubMed ID: 28660366
[TBL] [Abstract][Full Text] [Related]
16. Safety and efficacy of generic cyclosporine arpimune in Filipino low-risk primary kidney transplant recipients.
Pamugas GE; Danguilan RA; Lamban AB; Mangati VB; Ona ET
Transplant Proc; 2012 Jan; 44(1):101-8. PubMed ID: 22310590
[TBL] [Abstract][Full Text] [Related]
17. First clinical experience with the new once-daily formulation of tacrolimus.
First MR
Ther Drug Monit; 2008 Apr; 30(2):159-66. PubMed ID: 18367975
[TBL] [Abstract][Full Text] [Related]
18. The generics in transplantation and the rules on their use.
Masri M
Exp Clin Transplant; 2003 Jun; 1(1):65-8. PubMed ID: 15859910
[TBL] [Abstract][Full Text] [Related]
19. Tacrolimus trough levels and level-to-dose ratio in stable renal transplant patients converted to a once-daily regimen.
Meçule A; Tinti F; Poli L; Bachetoni A; Umbro I; Nofroni I; Lai Q; Pretagostini R; Berloco PB; Mitterhofer AP
Transplant Proc; 2011 May; 43(4):1024-7. PubMed ID: 21620042
[TBL] [Abstract][Full Text] [Related]
20. Generic tacrolimus in solid organ transplantation.
Taube D; Jones G; O'Beirne J; Wennberg L; Connor A; Rasmussen A; Backman L
Clin Transplant; 2014 May; 28(5):623-32. PubMed ID: 24750309
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
